P L Wander1, D A Enquobahrie2, C C Pritchard3, B McKnight4, K Rice4, M Christiansen5, R N Lemaitre5, T Rea6, D Siscovick7, N Sotoodehnia8. 1. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Seattle, WA, USA. Electronic address: lwander@u.washington.edu. 2. Department of Epidemiology, University of Washington, Seattle, WA, USA. 3. Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. 4. Department of Biostatistics, University of Washington, Seattle, WA, USA. 5. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA. 6. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA; Public Health-Seattle and King County, Emergency Medical Services Division, Seattle, WA, USA. 7. New York Academy of Medicine, New York, NY, USA. 8. Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract
AIM: MicroRNAs (miRNAs) have regulatory functions in organs critical in resuscitation from sudden cardiac arrest due to ventricular fibrillation (VF-SCA); therefore, circulating miRNAs may be markers of VF-SCA outcome. METHODS: We measured candidate miRNAs (N=45) in plasma using qRT-PCR among participants of a population-based VF-SCA study. Participants were randomly selected cases who died in the field (DF, n=15), died in hospital (DH, n=15), or survived to discharge (DC, n=15), and, age-, sex-, and race-matched controls (n=15). MiRNA levels were compared using ANOVA, t-tests, and fold-changes. RESULTS: Mean age of groups ranged from 66.9 to 69.7. Most participants were male (53-67%) and white (67%). Comparing cases to controls, plasma levels of 17 miRNAs expressed in heart, brain, liver, and other tissues (including miR-29c, -34a, -122, -145, -200a, -210, -499-5p, and -663b) were higher and three non-specific miRNAs lower (miR-221, -330-3p, and -9-5p). Among DH or DC compared with DF cases, levels of two miRNAs (liver-specific miR-122 and non-specific miR-205) were higher and two heart-specific miRNAs (miR-208b and -499-5p) lower. Among DC vs. DF cases, levels of three miRNAs (miR-122, and non-specific miR-200a and -205) were higher and four heart-specific miRNAs (miR-133a, -133b, -208b, and -499-5p) lower. Among DC vs. DH cases, levels of two non-specific miRNAs (miR-135a and -9-3p) were lower. CONCLUSIONS: Circulating miRNAs expressed in heart, brain, and other tissues differ between VF-SCA cases and controls and are related to resuscitation outcomes. Measurement of miRNAs may clarify mechanisms underlying resuscitation, improve prognostication, and guide development of therapies. Results require replication. Published by Elsevier Ireland Ltd.
AIM: MicroRNAs (miRNAs) have regulatory functions in organs critical in resuscitation from sudden cardiac arrest due to ventricular fibrillation (VF-SCA); therefore, circulating miRNAs may be markers of VF-SCA outcome. METHODS: We measured candidate miRNAs (N=45) in plasma using qRT-PCR among participants of a population-based VF-SCA study. Participants were randomly selected cases who died in the field (DF, n=15), died in hospital (DH, n=15), or survived to discharge (DC, n=15), and, age-, sex-, and race-matched controls (n=15). MiRNA levels were compared using ANOVA, t-tests, and fold-changes. RESULTS: Mean age of groups ranged from 66.9 to 69.7. Most participants were male (53-67%) and white (67%). Comparing cases to controls, plasma levels of 17 miRNAs expressed in heart, brain, liver, and other tissues (including miR-29c, -34a, -122, -145, -200a, -210, -499-5p, and -663b) were higher and three non-specific miRNAs lower (miR-221, -330-3p, and -9-5p). Among DH or DC compared with DF cases, levels of two miRNAs (liver-specific miR-122 and non-specific miR-205) were higher and two heart-specific miRNAs (miR-208b and -499-5p) lower. Among DC vs. DF cases, levels of three miRNAs (miR-122, and non-specific miR-200a and -205) were higher and four heart-specific miRNAs (miR-133a, -133b, -208b, and -499-5p) lower. Among DC vs. DH cases, levels of two non-specific miRNAs (miR-135a and -9-3p) were lower. CONCLUSIONS: Circulating miRNAs expressed in heart, brain, and other tissues differ between VF-SCA cases and controls and are related to resuscitation outcomes. Measurement of miRNAs may clarify mechanisms underlying resuscitation, improve prognostication, and guide development of therapies. Results require replication. Published by Elsevier Ireland Ltd.
Authors: Menno Hoekstra; Christian A C van der Lans; Bente Halvorsen; Lars Gullestad; Johan Kuiper; Pål Aukrust; Theo J C van Berkel; Erik A L Biessen Journal: Biochem Biophys Res Commun Date: 2010-03-15 Impact factor: 3.575
Authors: Pascal Stammet; Emeline Goretti; Mélanie Vausort; Lu Zhang; Daniel R Wagner; Yvan Devaux Journal: Crit Care Med Date: 2012-12 Impact factor: 7.598
Authors: John B Redell; Anthony N Moore; Norman H Ward; Georgene W Hergenroeder; Pramod K Dash Journal: J Neurotrauma Date: 2010-11-23 Impact factor: 5.269
Authors: Baqer A Haider; Alexander S Baras; Matthew N McCall; Joshua A Hertel; Toby C Cornish; Marc K Halushka Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240
Authors: Liu Peng; Qiu Chun-guang; Li Bei-fang; Ding Xue-zhi; Wang Zi-hao; Li Yun-fu; Dang Yan-ping; Liu Yang-gui; Li Wei-guo; Hu Tian-yong; Huang Zhen-wen Journal: Diagn Pathol Date: 2014-05-01 Impact factor: 2.644
Authors: Ludwig Christian Hinske; Gustavo S França; Hugo A M Torres; Daniel T Ohara; Camila M Lopes-Ramos; Jens Heyn; Luiz F L Reis; Lucila Ohno-Machado; Simone Kreth; Pedro A F Galante Journal: Database (Oxford) Date: 2014-10-06 Impact factor: 3.451